Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Feldman Eric Jay

2. Date of Event Requiring Statement (MM/DD/YYYY) 3/1/2021

3. Issuer Name and Ticker or Trading Symbol

GLYCOMIMETICS INC [GLYC]

(Last) (First) (Middle)

C/O GLYCOMIMETICS, INC, 9708 MEDICAL CENTER DRIVE

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
Chief Medical Officer /

(Street)

ROCKVILLE, MD 20850

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock ⁽¹⁾	50498	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Employee Stock Option (right to buy)	⁽²⁾	4/16/2029	Common Stock	53000	$11.97	D
Employee Stock Option (right to buy)	⁽³⁾	1/21/2030	Common Stock	38000	$4.72	D
Employee Stock Option (right to buy)	⁽⁴⁾	1/19/2031	Common Stock	20000	$3.81	D
Employee Stock Option (right to buy)	⁽⁵⁾	2/18/2031	Common Stock	49000	$3.85	D

Explanation of Responses:
(1)	The security represents restricted stock units granted to the reporting person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
(2)	One-fourth of the shares vested on April 17, 2020; the balance of the shares vest in a series of thirty-six successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date.
(3)	One-fourth of the shares vested on January 22, 2021; the balance of the shares vest in a series of thirty-six successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date.
(4)	One-fourth of the shares vest on January 20, 2022; the balance of the shares vest in a series of thirty-six successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date.
(5)	One-fourth of the shares vest on February 19, 2022; the balance of the shares vest in a series of thirty-six successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Feldman Eric Jay C/O GLYCOMIMETICS, INC 9708 MEDICAL CENTER DRIVE ROCKVILLE, MD 20850			Chief Medical Officer